genie lyrics

genie lyrics (All times Eastern) Schedule subject to change and/or blackouts Monday, Nov. 25 COLLEGE BASKETBALL (MEN’S) 2:30 p.m. ESPN2 — Maui Invitational: Memphis vs. UConn, Quarterfinal, Maui, Hawaii 4 p.m. CBSSN — Sunshine Slam Beach Bracket: Fordham vs. Penn St., Semifinal, Daytona Beach, Fla. 5 p.m. ESPN2 — Maui Invitational: Colorado vs. Michigan St., Quarterfinal, Maui, Hawaii 6 p.m. FS1 — Fort Myers Tip-Off: Michigan vs. Virginia Tech, Semifinal, Fort Myers, Fla. 6:30 p.m. CBSSN — Sunshine Slam Beach Bracket: Clemson vs. San Francisco, Semifinal, Daytona Beach, Fla. 7 p.m. BTN — Green Bay at Ohio St. 8:30 p.m. FS1 — Fort Myers Tip-Off: Xavier vs. South Carolina, Semifinal, Fort Myers, Fla. 9 p.m. BTN — Little Rock at Illinois ESPNU — Maui Invitational: Iowa St. vs. Auburn, Quarterfinal, Maui, Hawaii 11:30 p.m. ESPN2 — Maui Invitational: Dayton vs. North Carolina, Quarterfinal, Maui, Hawaii COLLEGE BASKETBALL (WOMEN’S) Noon ESPN2 — Battle 4 Atlantis: TBD, Championship, Nassau, Bahamas 2:30 p.m. ESPNU — Battle 4 Atlantis: TBD, Third-Place Game, Nassau, Bahamas HIGH SCHOOL BASKETBALL (BOY’S) 7 p.m. ESPNU — The Five for the Fight National Hoopfest: Montverde Academy (Fla.) vs. Wasatch Academy (Utah), Pleasant Grove, Utah NBA BASKETBALL 7:30 p.m. NBATV — Dallas at Atlanta 10 p.m. NBATV — Oklahoma City at Sacramento NFL FOOTBALL 8:15 p.m. ABC — Baltimore at L.A. Chargers ESPN — Baltimore at L.A. Chargers ESPN2 — Baltimore at L.A. Chargers (MNF with Peyton and Eli) SOCCER (MEN’S) 3 p.m. USA — Premier League: West Ham United at Newcastle United The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .FanSided’s Chris Landers pitched a perfect break-glass-in-case-of-emergency QB option for Tigers head football coach Brian Kelly, since after losing Bryce Underwood to Michigan it can accurately be called an emergency in Baton Rouge right now, and his LSU offense: Louisiana’s own Arch Manning. Landers proposed the bombshell transfer portal possibility while operating under the hypothetical that Quinn Ewers returns to Texas. “Brian Kelly is a man in need of a lifeline right now, with his LSU team reeling after three straight losses and top 2025 QB Bryce Underwood flipping his commitment to Michigan on Thursday night,” Landers prefaced before saying, “And what a lifeline Manning would be, a guy who was just as sought-after as Underwood coming out of high school — and who just so happened to grow up nearby in New Orleans? “The Tigers weren't on Manning's initial list of finalists, which could be a sign that Manning is looking to get a little bit further away from home. But they have the recent track record in QB development, having put Jayden Daniels (and soon Garrett Nussmeier) into the NFL and churning out great receivers on a regular basis. There isn't much behind Nussmeier for 2025, and if Manning becomes available, LSU could take all that Underwood money and simply redirect it to the next best thing.” Horns247’s Chip Brown reported on November 21 that Ewers is expected to declare for the 2025 NFL draft. “I spoke to two sources close to Texas quarterback Quinn Ewers on Wednesday night who said they expect Ewers to enter the 2025 NFL Draft after this season, meaning Saturday's game against Kentucky (2:30 p.m., ABC) would be Ewers' last regular-season home game as a Longhorn,” Brown wrote. Manning would represent a dramatic upswing for a Kelly-led program with practically no narrative wins to stand in recent months besides early-season wins over Ole Miss and South Carolina. In truth, LSU is supposed to win those matchups every year given the program’s pedigree. With all that said, Manning could do worse than a school that turned two recent transfers, Joe Burrow and Jayden Daniels, into Heisman winners.CORPUS CHRISTI, Texas (AP) — Garry Clark scored 15 points as Texas A&M-Corpus Christi beat Stephen F. Austin 67-48 on Saturday night. Read this article for free: Already have an account? To continue reading, please subscribe: * CORPUS CHRISTI, Texas (AP) — Garry Clark scored 15 points as Texas A&M-Corpus Christi beat Stephen F. Austin 67-48 on Saturday night. Read unlimited articles for free today: Already have an account? CORPUS CHRISTI, Texas (AP) — Garry Clark scored 15 points as Texas A&M-Corpus Christi beat Stephen F. Austin 67-48 on Saturday night. Clark had 12 rebounds for the Islanders (6-4, 1-1 Southland Conference). Owen Dease went 3 of 3 from the field to add 10 points. Jordan Roberts had 10 points and shot 4 for 9. Nana Antwi-Boasiako led the Lumberjacks (5-5, 0-2) in scoring, finishing with 13 points, 10 rebounds and three blocks. Clayton Southwick added 10 points and two steals. Myles Jenkins had five points. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. Advertisement

China is sharpening its electronic warfare blades against the US Navy, targeting critical sensors and radars to disrupt the Americans’ high-tech battle networks in a race for all-domain battlefield dominance. This month, the South China Morning Post that China’s People’s Liberation Army has unveiled a detailed list of US naval targets, including radars and sensors, for potential electronic warfare attacks against US aircraft carrier strike groups. SCMP says this “kill list,” published in the latest issue of Defense Industry Conversion in China, highlights the PLA’s strategy for disrupting the US Navy’s Cooperative Engagement Capability (CEC) system, a critical component of the fleet’s air defense and early warning network. According to SCMP, Mo Jiaqian, an electronic countermeasures expert with the PLA’s 92728 Unit, authored the report and outlined how the CEC’s reliance on wireless communication links makes it vulnerable to electronic interference. SCMP says key targets mentioned in the report include the AN/SPY-1 phased array radar on Aegis ships and the E-2C Hawkeye early warning aircraft. SCMP says the PLA aims to exploit these weaknesses to access the US military network and disrupt operations. It mentions that this development underscores the growing technological rivalry between China and the US, with China leveraging its advanced electronic devices for military applications. The report says the US has responded with sanctions on Chinese enterprises, inadvertently accelerating China’s military-civilian integration. Interfering with wireless communication links and exploiting them to access adversary networks shows the increasing convergence of electronic and cyber warfare. In an August 2019 report, the US Congressional Research Service (CRS) that the convergence of cyberspace operations and electronic warfare reflects a shift in military doctrine as both disciplines aim to dominate the electromagnetic spectrum. While the report notes that cyberspace operations and electronic warfare are historically distinct, technological advances have blurred their boundaries, enabling cross-functional capabilities. It points out that while cyberspace operations traditionally employ software to disrupt or control networked systems, electronic warfare uses electromagnetic energy to jam, intercept or manipulate communications. However, the report says modern operations increasingly see cyberspace operations and electronic warfare as supporting each other, such as transmitting computer code via radio frequencies to compromise adversary networks. For example, it mentions that the US EC-130H Compass Call aircraft, initially designed to jam enemy communications, now transmits malicious code to wireless devices. This multi-domain approach to attacking networks underscores the development of multi-domain operation (MDO) “kill chains”—the process of detecting, identifying, and engaging military targets. Such chains may herald a new arms race between the US and China. In the 2020 , , Christian Brose argues that the evolving race to develop kill chains marks a seismic shift in military strategy. Brose says that, unlike traditional arms races focused on hardware like battleships or nuclear weapons, this competition centers on cognitive superiority and decision-making speed. He mentions that the US and China are racing to master technologies such as AI, quantum computing and advanced sensors that can accelerate and automate the kill chain. The goal, Brose says, is to close the kill chain faster than the adversary while disrupting their ability to do the same. Brose argues that this arms race is not just about weapons but about controlling the flow of information — turning human intent into battlefield action with unprecedented speed. In line with the multi-domain kill chain arms race, Asia Times in February 2024 that the US Department of Defense (DoD) had achieved a significant milestone with the initial readiness of the Combined Joint All-Domain Command and Control (CJADC2) system, a cutting-edge initiative aimed at enhancing military interoperability and AI integration across all warfare domains. This development marks a crucial step in the US DoD’s strategy to outmaneuver technologically advanced adversaries such as China. The CJADC2 system connects sensors from all armed forces branches into a unified network, enabling faster and more accurate decision-making. The US fiscal 2024 budget allocates USD 1.4 billion for CJADC2, underscoring its transformative potential. The system’s AI-driven capabilities enable rapid collection, analysis, and dissemination of battlefield information, allowing for swift identification and targeting of threats. This evolution builds on the older Joint All-Domain Command and Control (JADC2) concept, emphasizing interoperability with allies and partners. The initiative aims to create an information-fluent force capable of dominating networks and executing precise strikes from diverse locations. In response to the US CJADC2 concept, Asia Times in April 2024 that China developed its Multi-Domain Precision Warfare (MDPW) concept that integrates advanced technologies such as AI, quantum computing and big data into its military strategy to identify and exploit vulnerabilities in US operational systems. China’s MDPW strategy leverages a comprehensive C4ISR network to coordinate precise strikes across various domains, including cyber and space, to disrupt and dismantle the US military’s command and control infrastructure, thereby gaining a strategic advantage. However, these MDO concepts might become the latest military intellectual boondoggle, promising much while based on faulty assumptions. In a January 2024 War on the Rocks , Davis Ellison and Tim Swejis argue that MDO, while innovative, faces significant challenges in practical implementation. They point out that the primary criticisms include the lack of a clear theory of success, technological immaturity and vague threat descriptions. They highlight that MDO often relies on optimistic assumptions about technological capabilities, such as assured connectivity and rapid data processing, which are not yet fully realized. Additionally, they mention that the concept’s broad and sometimes ambiguous language leads to confusion and inconsistency across different military branches and allied nations. Ellison and Swejis argue that the absence of specific adversary identification further complicates the development of effective MDO strategies. They also point out that MDO’s emphasis on speed and precision may overlook the complexities of real-world combat, where attrition and the fog of war remain significant factors. They also question MDO’s integration within existing political and military structures, with concerns about inter-service rivalry and the feasibility of whole-of-government approaches. Ultimately, Ellison and Swejis warn that without addressing these issues, MDO risks becoming another overhyped military concept that fails to deliver on its promises, potentially diverting attention and resources from more pressing strategic and operational challenges.Nano Nuclear Energy (NASDAQ:NNE) Shares Up 2.9% – Here’s What Happened

Wild host the Predators after Spurgeon's 2-goal performance

Ereauna Hardaway has heard the same message over and over from just about everyone the last few weeks. North Texas’ coaches, her teammates, her parents, they’re all telling the Mean Green’s point guard to be aggressive. “They’ve all helped me” Hardaway said following UNT’s 87-54 win over Southern Illinois on Saturday at the Super Pit. “They keep telling me to shoot the ball.” The message makes a lot of sense considering the way the junior guard is shooting of late. Hardway scored 21 points during the Mean Green’s win over the Salukis and led an offensive onslaught by UNT, which has come on of late. UNT (7-2) has cleared the 80-point mark in each of its last two games. Hardaway has scored a career high in both of those games, a run that began with an 18-point outing in a win over Tennessee State. Hardaway is in her fourth year at UNT, but the Mean Green have several newcomers who appear to be settling in. “Familiarity is helping us,” UNT coach Jason Burton said. “The work matters. Shooting, getting reps and making adjustments offensively have helped us. We are getting more comfortable with ourselves too. People are getting more comfortable with their roles.” The result was an impressive all-around offensive outing. UNT shot 56.1% (32-for-57) from the floor and had four players score in double figures. Kyla Deck scored 19, Tommisha Lampkin 17 and Desiree Wooten 11. Deck is one of UNT’s newcomers who have come on as the season has progressed. The Stephen F. Austin transfer also credited the support of her teammates and coaches, while also pointing to the work UNT is doing in practice. “The more practice we get, the better we get,” Deck said. “We have played some good teams and faced adversity. That brings teams together. It’s coming together. We’re getting better every single day.” UNT showed that improvement with another solid all-around offensive game. “We only turned the ball over 12 times and were plus-10 on rebounds,” Burton said. “Those extra possessions, with the way we are shooting the ball, will lead to us scoring and pulling away. “If we take care of the ball, good things are going to happen for us.” North Texas 87, Southern Illinois 54 SOUTHERN ILLINOIS (2-5) – Palmqvist 4-6 1-2 10, Uchenna 4-9 2-2 10, Cooper 2-9 0-0 5, Curman 0-3 0-0 0, Nelson 3-6 1-2 7, Almond 4-9 1-2 13, Brown 4-8 0-0 9, Gaines 0-0 0-0 0, Ngoyi 0-1 0-0 0, Agba 0-1 0-0 0, Peagler 0-0m 0-0 0. Totals 21-52 5-8 54. NORTH TEXAS (7-2) – Lampkin 8-10 1-3 17, Johnson 3-4 0-0 6, Hardaway 7-14 5-6 21, Wooten 4-7 3-4 11, Deck 6-12 6-8 19, Brackens 0-1 1-2 1, Price 1-3 2-2 4, Moore 1-2 0-0 3, Talley 2-3 1-2 5, McGrew 0-1 0-0 0, Brannon 0-0 0-0 0. Totals 32-57 19-27 87. Three-point goals – Southern Illinois – 7-20 (Palmqvist 1-3, Cooper 1-4, Curman 0-3, Almond 4-5, Brown 1-5) UNT 4-14 (Johnson 0-1, Hardaway 2-3, Wooten 0-2, Deck 1-4, Brackens 0-1, Moore 1-2, McGrew 0-1) Fouled out – none Rebounds – Southern Illinois 25 (Uchenna 6) UNT 36 (Johnson, Wooten 6) Assists – Southern Illinois 12 (Curman 4) UNT 14 (Wooten 4) Total fouls – Southern Illinois 21, UNT 16 A – 1,673. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request.ChefRobot UltraCook: 15-in-1 Smart Food Processor with $200 DiscountThe dynamics of the germ cell tumors market are anticipated to change in the coming years owing to the approval of specialized therapies for GCT and anticipated greater patients getting access to treatment across the world. Some key players such as Exelixis (Cabozantinib), Daiichi Sankyo (DS-9606), and HiFiBiO Therapeutics (HFB200301) are investigating their candidates to treat GCT in the 7MM. LAS VEGAS , Dec. 18, 2024 /PRNewswire/ -- DelveInsight's Germ Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, germ cell tumors emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan]. Key Takeaways from the Germ Cell Tumors Market Report According to DelveInsight's analysis, the market size for germ cell tumors in the 7MM is expected to reach ~ USD 630 million by 2034. Cabozantinib is expected to garner the largest market share of USD 129 million in the US by 2034, followed closely by DS-9606a , with a market share of USD 63 million . The incidence of GCT is around 26,000 cases in the 7MM in 2023. Leading germ cell tumors companies such as AstraZeneca, Exelixis, Pfizer, Xencor, Inc., Daiichi Sankyo, HiFiBiO Therapeutics, and others are developing novel germ cell tumors drugs that can be available in the germ cell tumors market in the coming years. The promising germ cell tumor therapies in the pipeline include Cabozantinib, Talazoparib, XmAb541, DS-9606a, and HFB200301, among others. Discover which therapies are expected to grab the major Germ Cell Tumors market share @ Germ Cell Tumors Market Report Germ Cell Tumors Overview Germ cell tumors are a rare type of growth that originates from germ cells, the cells responsible for developing into sperm in males and eggs in females. These tumors can be benign or malignant and often develop in the gonads, but they can also arise in other areas of the body, such as the abdomen, chest, or brain. The exact cause of germ cell tumors is not always clear, but genetic and environmental factors may play a role. Some known risk factors include abnormal development of the gonads, family history of similar conditions, and certain inherited syndromes. Germ cell tumor symptoms depend on the tumor's location and size. Common signs include swelling or a mass in the affected area, abdominal or chest pain, difficulty breathing (in cases of tumors in the chest), or hormonal changes. In some cases, the tumors may cause symptoms such as fatigue or unexplained weight loss. Germ cell tumor diagnosis typically involves a combination of imaging studies, blood tests to measure tumor markers like alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (β-hCG), and biopsy or surgical removal of the tumor to determine its nature. Early detection and treatment are crucial for improving outcomes, with therapies including surgery, chemotherapy, radiation, or a combination of these approaches. Germ Cell Tumors Epidemiology Segmentation The germ cell tumors epidemiology section provides insights into the historical and current germ cell tumors patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The germ cell tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of GCT Type-specific Incident Cases of GCT Sub-type specific Cases of Gonadal GCT Age-specific Cases of GCT Gender-specific Incident Cases of GCTs Total Incident Cases of GCTs by Stage Total Treatable Cases of GCT Line-wise Treatable Cases of GCT Germ Cell Tumors Treatment Market The treatment approach for germ cell tumors depends on the tumor type, whether ovarian or testicular. Surgery, followed by chemotherapy and sometimes radiation therapy, forms the cornerstone of GCT management. For recurrent testicular cancer, a chemotherapy combination of ifosfamide (Ifex), paclitaxel (Taxol), and cisplatin (Platinol) has proven highly effective. Notably, testicular cancers were among the first cancers successfully treated with radiation or chemotherapy. Over 80% of patients with metastatic germ cell tumors achieve a cure with cisplatin-based chemotherapy, typically the bleomycin, etoposide, and cisplatin (BEP) regimen, combined with surgery for residual disease. However, only about 25% of patients who relapse attain long-term survival after second-line cisplatin-based therapy, often using the vinblastine, ifosfamide, and cisplatin (VeIP) regimen. BEP remains the standard first-line chemotherapy for GCTs, effective in both seminomas and nonseminomas. This regimen capitalizes on cisplatin's DNA-damaging properties, etoposide's inhibition of DNA synthesis, and bleomycin's ability to induce DNA strand breaks, resulting in high cure rates. Treatment typically involves 3 to 4 cycles, tailored to disease stage and risk factors. Advancements in surgical techniques, rising incidence rates, and improved post-surgical outcomes have increased the demand for surgical interventions, driving growth in the broader GCT treatment market. To know more about germ cell tumor treatment guidelines, visit @ Germ Cell Tumors Management Germ Cell Tumors Pipeline Therapies and Key Companies Durvalumab + Tremelimumab: AstraZeneca Cabozantinib: Exelixis Talazoparib: Pfizer XmAb541: Xencor, Inc. DS-9606a: Daiichi Sankyo HFB200301: HiFiBiO Therapeutics Discover more about germ cell tumor drugs in development @ Germ Cell Tumors Clinical Trials Germ Cell Tumors Market Dynamics The germ cell tumors market dynamics are expected to change in the coming years. Platinum-based chemotherapy , such as the BEP regimen, is highly effective in treating both early and advanced-stage germ cell tumors, while surgical interventions like orchiectomy or oophorectomy also contribute significantly to successful outcomes. Biomarkers such as AFP, hCG, and LDH play a crucial role in diagnosis, staging, and monitoring treatment response, facilitating enhanced clinical decision-making and personalized care. Ongoing research into the genetic and molecular drivers of GCTs holds promise for developing highly effective, less toxic therapies, particularly for refractory or relapsed cases. Furthermore, identifying and validating new biomarkers could improve diagnosis, risk stratification, and relapse detection , advancing personalized treatment approaches for patients, including those with non-secretory tumors. Furthermore, potential therapies are being investigated for the treatment of germ cell tumors, and it is safe to predict that the treatment space will significantly impact the germ cell tumors market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the germ cell tumors market in the 7MM. However several factors may impede the growth of the germ cell tumors market. Platinum-based chemotherapy is highly effective but is associated with significant acute toxicities , such as nephrotoxicity and ototoxicity, as well as long-term effects like secondary malignancies, which can severely impact the quality of life, particularly for young survivors. Additionally, approximately 10–15% of patients develop resistance to first-line therapies , leaving them with few effective options, as salvage treatments are often toxic and have limited success rates. The emergence of resistance to platinum-based chemotherapy, especially in advanced or metastatic cases, poses a significant challenge, threatening the high cure rates associated with GCTs . Furthermore, the cost of advanced therapies , including novel drugs and long-term survivorship care, places a substantial financial burden on patients and healthcare systems, potentially limiting access to effective treatments. Moreover, germ cell tumor treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, germ cell tumors market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact germ cell tumors market growth. Scope of the Germ Cell Tumors Market Report Therapeutic Assessment: Germ Cell Tumors current marketed and emerging therapies Germ Cell Tumors Market Dynamics: Key Market Forecast Assumptions of Emerging Germ Cell Tumors Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Germ Cell Tumors Market Access and Reimbursement Download the report to understand which factors are driving germ cell tumors market trends @ Germ Cell Tumors Market Trends Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NSCLC companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Small Cell Lung Cancer Market Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm , Carrick Therapeutics, among others. Small-cell Lung Cancer Pipeline Small-cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm , Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLP

Swinney and Brown at memorial service for ‘giant of a man’ Alex SalmondRenewable Energy Consultancy Service Market Set for Explosive Growth | Tetra Tech, AECOM, Clean Edge

NEW YORK — United States Rep. Ritchie Torres says he's "open to" running for governor in New York after questioning the actions of Gov. Kathy Hochul and Mayor Eric Adams. Torres has been highly critical of the job Hochul is doing. "We've seen a rise in crime in New York state and New York City. If she calls that governing, the majority of New Yorkers aren't impressed," he said. Torres wrote a letter to the governor and the mayor , claiming they were complicit in the release of Ramon Rivera, who fatally stabbed three people in New York City last week . Hochul reacted to the letter Tuesday, saying, "I'm not politicizing that tragedy. I refuse to politicize what was a horrific attack destroying families just before the holidays." When asked about the possibility that Torres was using the attack as a springboard to a political campaign against her, Hochul said, "I actually don't care what he's doing." Torres, meanwhile, said, "I've made no decision to run for governor. I'm open to it, but I've made no final decision." Adams was also asked about Torres' charges that the city failed to keep Rivera in prison despite his assault of a correction officer. "I can understand the concerns that the congressman raised and others have raised, but we can't be revisionist. I don't think there has been an elected official in the city that has been more vociferous around people with severe mental health illness ," he said. Both the governor and the mayor insist the city has increased services for those struggling with mental health issues . On social media late Tuesday afternoon , Torres said he had a productive conversation with the mayor, and he supports the mayor's efforts to build mental health institutions in the city. Marcia Kramer joined CBS News New York in 1990 as an investigative and political reporter. Prior to CBS2, she was the City Hall bureau chief at the New York Daily News.Confluent's chief accounting officer sells $59,170 in stockSwinney and Brown at memorial service for ‘giant of a man’ Alex Salmond